MSICS Pharma invites researchers to submit proposals on psilocybin-based studies for PTSD treatment
Funding and GMP-grade psilocybin (MSX-06) will be provided to selected projects
To revolutionize global mental healthcare, we harness the power of naturally-sourced Psilocybin, producing cutting-edge products tailored for pharmaceutical applications, to effectively address the world's pressing health needs
MSICS operates an innovative GMP production facility producing MSX-06 - MSICS's flagship naturally-sourced Psilocybin product
MSX-06 is currently undergoing trials in collaboration with renowned hospitals, to treat medical conditions such as depression, OCD, anxiety, and eating disorders
